Ovarian Neoplasms: all 2,757 studies
Page 8 of 28. Open to participants first (735), then studies with results posted, then the rest; newest registration first within each.
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingNCT03564340Phase 1/2
- Genetic Education in BRCA FamiliesEnrolling by invitationNCT03544983Not applicable
- HIPEC After Initial CRS in Patients Who Have Received NACTRecruitingNCT03540017Phase 1
- The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in TamponsRecruitingNCT03538665
- Signal TrAnsduction Pathway Activity Analysis in OVarian cancERRecruitingNCT03458221Phase 2/3
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 2
- Intervention of Ovarian Cancer With Antigen-specific Engineered Immune EffectorsEnrolling by invitationNCT03393962Phase 1/2
- Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2RecruitingNCT03296826
- HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval LaparotomyRecruitingNCT03275194Phase 2
- Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian CancerRecruitingNCT03025477Phase 2
- Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)RecruitingNCT03017573Not applicable
- Prognostic and Predictive Biomarkers in Ovarian CancersRecruitingNCT03010124Not applicable
- Institut Paoli Calmettes Ovarian Cancer DatabaseRecruitingNCT02869568
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
- KOrean Borderline Ovarian Tumor (KOBOT) RegistryRecruitingNCT02803970
- Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching HostRecruitingNCT02732860
- Efficacy of Lifestyle Intervention in BRCA1/2 Mutation CarriersRecruitingNCT02516540Not applicable
- TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal TumorsRecruitingNCT02429700Phase 3
- TC or BEP in Treating Patients With Malignant Ovarian Germ Cell TumorsRecruitingNCT02429687Phase 3
- Cancer Experience Registry (CER) for Cancer Patients and CaregiversRecruitingNCT02333604
- DOvEE - Diagnosing Ovarian & Endometrial Cancer EarlyRecruitingNCT02296307
- DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using GenomicsRecruitingNCT02288676
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
- Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruitingNCT01950572
- Establishment of a Tumor Bank for Tissue SamplesRecruitingNCT01789229
- Establishment of a Tumor Bank for Blood SamplesRecruitingNCT01763125
- Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisRecruitingNCT01441089
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood SamplesRecruitingNCT01034033
- Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial CancerRecruitingNCT01000259
- Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic TumorsRecruitingNCT00722228Phase 1/2
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruitingNCT00539162Not applicable
- Data Collection for Patients With Low Grade Ovarian or Peritoneal TumorsRecruitingNCT00488878
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruitingNCT00005095
- SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive SurgeryCompletedNCT07241091Not applicableResults posted
- A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)TerminatedNCT06964165Phase 2Results posted
- A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerTerminatedNCT06630325Phase 2Results posted
- A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid TumorsActive, not recruitingNCT06390995Phase 1/2Results posted
- Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid TumorCompletedNCT06048367Phase 1Results posted
- Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian CancerCompletedNCT05979298Phase 2Results posted
- A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/2Results posted
- Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results posted
- EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerActive, not recruitingNCT05715216Phase 2Results posted
- MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT05708924Phase 1Results posted
- Assessing the Time Demands of CancerActive, not recruitingNCT05708703Results posted
- A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT05613088Phase 2Results posted
- A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsTerminatedNCT05572684Phase 1/2Results posted
- Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A MutationTerminatedNCT05523440Phase 2Results posted
- Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersCompletedNCT05483933Phase 1Results posted
- A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerTerminatedNCT05451849Phase 1/2Results posted
- Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)CompletedNCT05446870Phase 2Results posted
- Nirogacestat in Ovarian Granulosa Cell TumorsCompletedNCT05348356Phase 2Results posted
- Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian CancerActive, not recruitingNCT05276973Phase 1Results posted
- Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian CancerTerminatedNCT05261490Phase 1/2Results posted
- Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)CompletedNCT05259696Phase 1/2Results posted
- A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerCompletedNCT05258747Phase 1Results posted
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerActive, not recruitingNCT05257408Phase 3Results posted
- A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsTerminatedNCT05256381Phase 2Results posted
- Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsTerminatedNCT05194735Phase 1/2Results posted
- Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisCompletedNCT05185947Phase 2Results posted
- Michigan Genetic Hereditary Testing (MiGHT)CompletedNCT05162846Not applicableResults posted
- Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).Active, not recruitingNCT05116189Phase 3Results posted
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedNCT05092360Phase 3Results posted
- Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedNCT05082025Phase 2Results posted
- A Study of PF-07260437 in Advanced or Metastatic Solid TumorsTerminatedNCT05067972Phase 1Results posted
- Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersCompletedNCT05041257Phase 2Results posted
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)CompletedNCT05007106Phase 2Results posted
- A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid TumorsCompletedNCT05001347Phase 2Results posted
- Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression ParticipantsTerminatedNCT04939701Phase 1/2Results posted
- Connecting Families to Overcome Ovarian CancerCompletedNCT04927013Not applicableResults posted
- HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of GenomicsActive, not recruitingNCT04905082Not applicableResults posted
- A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid TumorsTerminatedNCT04875806Phase 1/2Results posted
- A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsCompletedNCT04853017Phase 1Results posted
- Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04781088Phase 2Results posted
- Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04753216Phase 2Results posted
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedNCT04729387Phase 3Results posted
- CATCH-R: A Rollover Study to Provide Continued Access to RucaparibCompletedNCT04676334Phase 3Results posted
- Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial OvarianActive, not recruitingNCT04670068Phase 1Results posted
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
- FT516 and IL2 With Enoblituzumab for Ovarian CancerCompletedNCT04630769Phase 1Results posted
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsActive, not recruitingNCT04616534Phase 1Results posted
- T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedNCT04611126Phase 1/2Results posted
- Dose Escalation of Lapatinib With Paclitaxel in Ovarian CancerCompletedNCT04608409Phase 1Results posted
- BrUOG 390: Neoadjuvant Treatment With TalazoparibTerminatedNCT04598321Phase 1Results posted
- REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related FatigueCompletedNCT04525183Not applicableResults posted
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
- PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian CancerTerminatedNCT04493619Phase 1/2Results posted
- Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)CompletedNCT04492007Not applicableResults posted
- A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid TumorsTerminatedNCT04408599Phase 1/2Results posted
- Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian CancerCompletedNCT04406623Phase 1Results posted
- Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian CancerTerminatedNCT04377087Phase 2Results posted
- Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant ChemotherapyCompletedNCT04352439Phase 4Results posted
- Zafirlukast in Treatment of Marker Relapsed Ovarian CancerCompletedNCT04339140Phase 2Results posted
- NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT04332653Phase 1/2Results posted
- Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast CancerCompletedNCT04330040Phase 4Results posted
- Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By GenomicsTerminatedNCT04315233Phase 1Results posted
- A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionCompletedNCT04296890Phase 3Results posted
- Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.CompletedNCT04283773Results posted
- Optimal Timing of BR55 CEUS of the OvariesTerminatedNCT04248153Phase 2Results posted